Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedFeb 07, 2026
DataAggregated Company Financials
Companies9
- 7D-1.3%
- 3M12.8%
- 1Y40.2%
- YTD3.7%
Over the last 7 days, the Biotech industry has dropped 1.3%, driven by a pullback from Nykode Therapeutics of 4.7%. On the other hand Norda is actually up 5.1%. This takes the industry's 12 month performance to a gain of 40%. Earnings are forecast to grow by 22% annually.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 08 Feb 2026 | NOK 5.6b | NOK 604.0m | -NOK 363,650,151.78 | 79.4x | -15.3x | 9.2x |
| Tue, 06 Jan 2026 | NOK 5.4b | NOK 606.7m | -NOK 367,665,991.80 | 77.9x | -14.6x | 8.9x |
| Thu, 04 Dec 2025 | NOK 4.9b | NOK 606.9m | -NOK 368,055,132.54 | 78.3x | -13.2x | 8x |
| Sat, 01 Nov 2025 | NOK 4.9b | NOK 607.5m | -NOK 412,560,112.66 | 264.9x | -11.8x | 8x |
| Mon, 29 Sep 2025 | NOK 4.6b | NOK 611.6m | -NOK 517,428,993.47 | 234.9x | -8.8x | 7.5x |
| Wed, 27 Aug 2025 | NOK 4.7b | NOK 617.2m | -NOK 583,886,080.63 | 266.8x | -8.1x | 7.6x |
| Fri, 25 Jul 2025 | NOK 4.9b | NOK 885.3m | -NOK 745,488,655.39 | 209.6x | -6.6x | 5.5x |
| Sun, 22 Jun 2025 | NOK 4.8b | NOK 885.3m | -NOK 745,251,650.83 | 197.3x | -6.5x | 5.5x |
| Tue, 20 May 2025 | NOK 5.1b | NOK 895.9m | -NOK 889,348,797.99 | 193.2x | -5.8x | 5.7x |
| Thu, 17 Apr 2025 | NOK 4.7b | NOK 521.6m | -NOK 1,026,394,831.66 | 114.7x | -4.6x | 9.1x |
| Sat, 15 Mar 2025 | NOK 4.8b | NOK 521.7m | -NOK 1,101,605,061.47 | 119.7x | -4.3x | 9.2x |
| Mon, 10 Feb 2025 | NOK 5.1b | NOK 457.1m | -NOK 1,121,416,201.72 | 154.5x | -4.6x | 11.2x |
| Wed, 08 Jan 2025 | NOK 4.7b | NOK 457.5m | -NOK 1,072,866,848.74 | 160x | -4.4x | 10.3x |
| Fri, 06 Dec 2024 | NOK 4.3b | NOK 456.3m | -NOK 1,062,528,187.90 | 146.8x | -4x | 9.3x |
| Sun, 03 Nov 2024 | NOK 4.6b | NOK 472.8m | -NOK 1,074,585,104.05 | 60.3x | -4.3x | 9.7x |
| Tue, 01 Oct 2024 | NOK 5.0b | NOK 469.5m | -NOK 1,048,902,067.05 | 62.3x | -4.8x | 10.7x |
| Thu, 29 Aug 2024 | NOK 6.1b | NOK 468.1m | -NOK 1,045,668,674.70 | 68.7x | -5.8x | 13x |
| Sat, 27 Jul 2024 | NOK 9.1b | NOK 517.9m | -NOK 1,056,629,205.47 | 71.9x | -8.6x | 17.6x |
| Mon, 24 Jun 2024 | NOK 8.9b | NOK 641.0m | -NOK 938,795,223.83 | 36.6x | -9.5x | 13.9x |
| Wed, 22 May 2024 | NOK 8.9b | NOK 638.7m | -NOK 977,936,959.21 | 33.3x | -9.1x | 13.9x |
| Fri, 19 Apr 2024 | NOK 8.2b | NOK 661.2m | -NOK 951,314,266.64 | 36.2x | -8.6x | 12.4x |
| Sun, 17 Mar 2024 | NOK 9.0b | NOK 655.4m | -NOK 935,914,720.54 | 40.8x | -9.6x | 13.7x |
| Tue, 13 Feb 2024 | NOK 15.1b | NOK 671.5m | -NOK 1,061,859,662.08 | 40.6x | -14.3x | 22.5x |
| Thu, 11 Jan 2024 | NOK 16.9b | NOK 655.0m | -NOK 1,354,915,811.00 | 59.4x | -12.5x | 25.8x |
| Sat, 09 Dec 2023 | NOK 15.1b | NOK 663.1m | -NOK 1,378,416,824.00 | 57.6x | -10.9x | 22.7x |
| Mon, 06 Nov 2023 | NOK 13.8b | NOK 491.0m | -NOK 1,549,505,083.00 | 93x | -8.9x | 28.1x |
| Wed, 04 Oct 2023 | NOK 15.1b | NOK 626.4m | -NOK 1,461,958,476.00 | 53.9x | -10.3x | 24.1x |
| Fri, 01 Sep 2023 | NOK 15.9b | NOK 627.2m | -NOK 1,435,114,831.00 | 60.3x | -11.1x | 25.4x |
| Sun, 30 Jul 2023 | NOK 16.3b | NOK 555.5m | -NOK 1,453,596,890.00 | 58.2x | -11.2x | 29.4x |
| Tue, 27 Jun 2023 | NOK 15.1b | NOK 561.6m | -NOK 1,478,386,871.00 | 57.3x | -10.2x | 26.8x |
| Thu, 25 May 2023 | NOK 17.2b | NOK 563.1m | -NOK 1,498,255,137.00 | 63.9x | -11.5x | 30.6x |
| Sat, 22 Apr 2023 | NOK 17.2b | NOK 540.4m | -NOK 1,450,699,590.00 | 30.8x | -11.8x | 31.8x |
| Mon, 20 Mar 2023 | NOK 15.0b | NOK 538.6m | -NOK 1,566,658,506.00 | 29.5x | -9.6x | 27.8x |
| Wed, 15 Feb 2023 | NOK 18.5b | NOK 813.3m | -NOK 1,414,518,929.00 | 33.5x | -13.1x | 22.8x |
Price to Earnings Ratio
-13.1x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 16.0x is higher than the industry's current PS ratio of 9.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 9.4% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | 2.65% | |
| Healthcare | -3.18% | |
| Biotech | -1.30% | |
| Biotech | -1.30% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NORD Norda | NOK 85.10 | 5.1% +NOK 21.0m | -11.4% | PE3.5x | |
| LYTIX Lytix Biopharma | NOK 9.52 | 0.4% +NOK 3.0m | 64.1% | PS1896.1x | |
| PCIB PCI Biotech Holding | NOK 0.19 | 22.9% +NOK 1.3m | -84.3% | PS1.5x | |
| EXTX EXACT Therapeutics | NOK 1.88 | 1.1% +NOK 1.3m | -48.6% | PB1.8x | |
| ZLNA Zelluna | NOK 15.00 | 0.01% +NOK 52.5k | n/a | PS7434.8x |